Genomic and Metabolomic Polymorphism among Experimentally Selected Paromomycin-Resistant Leishmania donovani Strains-Reference-Cited by-同舟云学术

Genomic and Metabolomic Polymorphism among Experimentally Selected Paromomycin-Resistant Leishmania donovani Strains

Published:2019-12-20 Issue:1 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Shaw C. D.¹,Imamura H.²,Downing T.³^ORCID,Blackburn G.⁴,Westrop G. D.¹,Cotton J. A.⁵,Berriman M.⁵,Sanders M.⁵,Rijal S.⁶,Coombs G. H.¹,Dujardin J. C.²⁷,Carter K. C.¹

Affiliation:

1. Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom

2. Instituut voor Tropische Geneeskunde Nationalestraat, Antwerp, Belgium

3. School of Biotechnology, Dublin City University, Dublin, Ireland

4. Wolfson Wohl Cancer Research Centre, University of Glasgow, Bearsden, United Kingdom

5. Wellcome Trust Sanger Institute, Hinxton, United Kingdom

6. BP Koirala Institute of Health Sciences, Dharan, Nepal

7. University of Antwerp, Antwerp, Belgium

Abstract

Understanding the mechanism(s) underpinning drug resistance could lead to novel treatments to reverse the increased tolerance of a pathogen. In this study, paromomycin (PMM) resistance (PMM r ) was induced in three Nepalese clinical strains of Leishmania donovani with different inherent susceptibilities to antimony (Sb) drugs by stepwise exposure of promastigotes to PMM.

Funder

National Science Foundation

Burroughs Wellcome Fund

EC | FP7 | FP7 Health

Belgian Federal Science Policy Office

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00904-19

Reference38 articles.

1. World Health Organization. 2019. Leishmaniasis. World Health Organization Geneva Switzerland. http://www.who.int/mediacentre/factsheets/fs375/en/. Accessed 19 February 2019.

2. Recent developments and future prospects in the treatment of visceral leishmaniasis

3. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine;Sangraula H;J Assoc Physicians India,2003

4. Leishmaniasis chemotherapy—challenges and opportunities

5. Increasing Failure of Miltefosine in the Treatment of Kala-azar in Nepal and the Potential Role of Parasite Drug Resistance, Reinfection, or Noncompliance

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A primer on correlation-based dimension reduction methods for multi-omics analysis;Journal of The Royal Society Interface;2023-10

2. Branched chain amino acids catabolism as a source of new drug targets in pathogenic protists;Experimental Parasitology;2023-06

3. In Vitro study of the leishmanicidal activity of perovskia abrotanoides terpenoid-rich fractions against Leishmania major (MRHO/IR/75/ER);Advanced Biomedical Research;2023

4. Miltefosine Unresponsiveness in Visceral Leishmaniasis;Challenges and Solutions Against Visceral Leishmaniasis;2023

5. Target-Based Rational Improvement Strategies and Pitfalls in Leishmania Drug Discovery;Natural Product Based Drug Discovery Against Human Parasites;2023